XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.99

-1.5%

Nov 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (14096)	7/16/2000 10:29:33 AM
From: Robert K.	Read Replies (1) of 17367

Cacaito> i seems you have a change of heart. Your comments> >>>>>>>>>.>>"But,the products could save ICU time, post surgery time, and money, it will not be a hard sale. The insurance companies are going to be lucky since it looks like three good products are coming: zovant, pafase, tifacogin, rbpi21 (well 4, ok), and there will be competition as years past by. rbpi21 if ever demonstrate the animal results in humans should have the advantages in the market since is a real killer of bugs, but this is a big IF and I am not betting on it (I can wait for the facts, no rush)." My comment> I tip my hat to you for having the guts to come to grips with the facts. Facts are bpi is unproven in human testing according to fda standards thusfar. But bpi is not proven not to work as you have previously claimed. There is a big difference. All IMO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next